SCHEMBL417484

SCHEMBL417484

O=C(O)C1CCC(O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14353832 1.00
SCHEMBL13262178 1.00
SCHEMBL417983 1.00
SCHEMBL2355666 1.00
SCHEMBL2237318 1.00
SCHEMBL28310590 1.00
SCHEMBL20344391 1.00
SCHEMBL2160534 1.00
SCHEMBL908618 0.85 ACE (0.39)
SCHEMBL404285 0.84 ANPEP (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111607023-A Method for removing residual metal catalyst in hydrogenated polymer 浙江众立合成材料科技股份有限公司 2020-09-01 CN claimed
EP-4687951-A1 P450-BM3 VARIANTS WITH IMPROVED ACTIVITY Codexis, Inc. (US) 2026-02-11 EP disclosed
EP-4506344-A1 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF Bebetter Med Inc. (CN) 2025-02-12 EP disclosed
US-20250034116-A1 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF BEBETTER MED INC. (CN) 2025-01-30 US disclosed
WO-2024196434-A1 P450-BM3 VARIANTS WITH IMPROVED ACTIVITY CODEXIS, INC. (US) 2024-09-26 WO disclosed
CN-116615417-B 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof 广州必贝特医药股份有限公司 2024-05-14 CN disclosed
CN-116615417-A 1, 4-diheterocycle substituted aromatic ring or aromatic heterocyclic compound and application thereof 广州必贝特医药股份有限公司 2023-08-18 CN disclosed
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
EP-4143235-A1 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION IncellDx, Inc. (US) 2023-03-08 EP disclosed
CN-111607023-B Method for removing residual metal catalyst in hydrogenated polymer 浙江众立合成材料科技股份有限公司 2022-11-04 CN disclosed
US-20020058201-A1 Radiation-sensitive resin composition JSR CORPORATION (JP) 2002-05-16 US disclosed
EP-1193558-A2 Radiation-sensitive resin composition JSR Corporation (JP) 2002-04-03 EP disclosed
WO-2002018319-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2002-03-07 WO disclosed
US-6020341-A Enediyne quinone imines and methods of preparation and use thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2000-02-01 US disclosed
EP-0793497-A4 NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF SLOAN KETTERING INST CANCER (US) 1998-01-28 EP disclosed
EP-0793497-A1 NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF Sloan-Kettering Institute For Cancer Research (US) 1997-09-10 EP disclosed
US-5622958-A ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1997-04-22 US disclosed
WO-1996016655-A1 NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1996-06-06 WO disclosed
US-4090019-A Geminal prostaglandin analogs MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1978-05-16 US disclosed
US-4089897-A Geminal prostaglandin analogs MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1978-05-16 US disclosed